

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TYK Medicines, Inc*

浙江同源康醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2410)

**INSIDE INFORMATION
APPLICATION FOR THE H SHARE FULL CIRCULATION
BY THE COMPANY**

This announcement is made by TYK Medicines, Inc* (浙江同源康醫藥股份有限公司) (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the China Securities Regulatory Commission (the “**CSRC**”) Announcement [2019] No. 22 “Guidelines on Application for ‘Full Circulation’ of Domestic Unlisted Shares of H-share Companies” 《(H股公司境內未上市股份申請“全流通”業務指引)》 issued by the CSRC on November 14, 2019 and amended on August 10, 2023 and the “Trial Administrative Measures for Overseas Securities Offering and Listing by Domestic Companies” 《(境內企業境外發行證券和上市管理試行辦法)》 issued by the CSRC on February 17, 2023 regarding the guidelines for procedures to apply for full circulation of shares by companies whose H shares are listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company has submitted an application (the “**Application**”) to the CSRC on September 13, 2024, in respect of the conversion of 173,641,645 unlisted shares (the “**Unlisted Shares**”) into H shares (the “**H Shares**”) of the Company and the listing of such shares on the Stock Exchange (the “**H Share Full Circulation**”). Subject to obtaining all the filings and/or approvals from relevant regulatory authorities (including but not limited to the CSRC and the Stock Exchange) and the compliance with all the applicable laws, regulations and rules, such Unlisted Shares shall

be converted into H Shares and be eligible to be listed and traded on the Main Board of the Stock Exchange, details of which are as follows:

Name of shareholders	Number of Unlisted Shares to be converted into H Shares	Approximate percentage ⁽¹⁾ of the Company's total issued share capital ⁽²⁾
Tetranov Pharmaceutical (Zhengzhou) Co., Ltd.*/ 鄭州泰基鴻諾醫藥股份有限公司	65,000,000	17.53%
Pivot Pharma Tech (Shanghai) Co., Ltd.*/ 貝沃特醫藥技術(上海)有限公司	5,362,500	1.45%
Chengdu Boyuan Jiayu Venture Capital Partnership (Limited Partnership)*/ 成都博遠嘉昱創業投資合夥企業(有限合夥)	5,981,019	1.61%
Changxing Liyuan Enterprise Management Partnership (Limited Partnership)*/ 長興利源企業管理合夥企業(有限合夥)	14,735,500	3.97%
Changsanjiao Tengyuan (Changxing) Medical Equity Investment Partnership (Limited Partnership)*/ 長三角騰遠(長興)醫療股權投資合夥企業(有限合夥)	8,190,000	2.21%
Zhuzhou Guochuang Junhe Investment Partnership (Limited Partnership)*/ 株洲市國創君和投資合夥企業(有限合夥)	3,510,000	0.95%
Xiamen Ronghui Hongshang Equity Investment Partnership (Limited Partnership)*/ 廈門融匯弘上股權投資合夥企業(有限合夥)	4,680,000	1.26%
Ningbo Fuqi Venture Capital Partnership (Limited Partnership)*/ 寧波複祺創業投資合夥企業(有限合夥)	4,680,000	1.26%
Shanghai Fanxi Enterprise Management Partnership (Limited Partnership)*/ 上海凡熹企業管理合夥企業(有限合夥)	390,000	0.11%
Huzhou Haibang Shuhu Venture Capital Partnership (Limited Partnership)*/ 湖州海邦數湖創業投資合夥企業(有限合夥)	1,996,800	0.54%
Changxing Guohai Donghu Equity Investment Partnership (Limited Partnership)*/ 長興國海東湖股權投資合夥企業(有限合夥)	9,139,200	2.46%
Zhuzhou Wenzhou Junzhe Venture Capital Partnership (Limited Partnership)*/ 株洲市文周君喆創業投資合夥企業(有限合夥)	3,328,000	0.90%
Jiaxing Xingren Equity Investment Partnership (Limited Partnership)*/ 嘉興行仁股權投資合夥企業(有限合夥)	1,547,619	0.42%

Name of shareholders	Number of Unlisted Shares to be converted into H Shares	Approximate percentage ⁽¹⁾ of the Company's total issued share capital ⁽²⁾
Hunan Xiangyi Investment Tongyuan No. 1 Venture Capital Partnership (Limited Partnership)*/ 湖南湘醫投同源壹號創業投資合夥企業(有限合夥)	3,095,238	0.83%
Shanghai Kaicheng Enterprise Management Consulting Partnership (Limited Partnership)*/ 上海凱乘企業管理諮詢合夥企業(有限合夥)	468,000	0.13%
Mr. JI Aining/ 吉愛寧	1,547,000	0.42%
Ningbo Meishan Bonded Port Area Houyang Tongchi Investment Management Partnership (Limited Partnership)*/ 寧波梅山保稅港區厚揚通馳投資管理合夥企業(有限合夥)	3,417,723	0.92%
Ningbo Meishan Bonded Port Area Houji Tongnuo Investment Management Partnership (Limited Partnership)*/ 寧波梅山保稅港區厚紀通諾投資管理合夥企業(有限合夥)	9,195,302	2.48%
Changxing Xingyin Equity Investment Partnership (Limited Partnership)*/ 長興興銀股權投資合夥企業(有限合夥)	6,509,948	1.76%
Shenzhen Yangzi Xinkang Pharmaceutical Investment Enterprise (Limited Partnership)*/ 深圳揚子鑫康醫藥投資企業(有限合夥)	4,068,718	1.10%
Yangzhou Zekang Equity Investment Partnership (Limited Partnership)*/ 揚州澤康股權投資合夥企業(有限合夥)	2,376,124	0.64%
Changxing Xinsheng Equity Investment Partnership (Limited Partnership)*/ 長興鑫晟股權投資合夥企業(有限合夥)	2,041,374	0.55%
Sichuan Huiyu Pharmaceutical Co., Ltd.*/ 四川匯宇製藥股份有限公司	6,804,580	1.83%
Changxing Caiyuan Enterprise Management Partnership (Limited Partnership)*/ 長興彩源企業管理合夥企業(有限合夥)	2,457,000	0.66%
Changxing Gangyuan Enterprise Management Partnership (Limited Partnership)*/ 長興罡源企業管理合夥企業(有限合夥)	3,120,000	0.84%
Total	173,641,645	46.82%

Note:

- (1) The percentages have been rounded up to the nearest two decimal places and any discrepancy between the totals and sums of amounts listed in the table is due to rounding.
- (2) The calculation is based on the total number of 370,835,818 shares of the Company in issue as of the date of this announcement.

Pursuant to the articles of association of the Company, no further shareholders' meeting is required to be convened to approve the H Share Full Circulation.

As of the date of this announcement, the Company has not completed the filing with the CSRC in respect of the Application. Further announcement(s) will be made on the progress and details of the Application and the H Share Full Circulation as and when appropriate.

The H Share Full Circulation is subject to other relevant procedures as required by the CSRC, the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
TYK Medicines, Inc*
(浙江同源康醫藥股份有限公司)
Dr. WU Yusheng

Chairman, Executive Director and Chief Executive Officer

Hong Kong, September 13, 2024

As at the date of this announcement, the Board comprises Dr. WU Yusheng and Dr. JIANG Mingyu as executive Directors, Dr. LI Jun, Dr. GU Eric Hong, Dr. MENG Xiaoying, Mr. HE Chao and Dr. DING Zhao as non-executive Directors, and Mr. ZHANG Senquan, Dr. LENG Yuting, Dr. XU Wenqing and Dr. SHEN Xiuhua as independent non-executive Directors.

* *For identification purpose only*